Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.
November 25, 2021 12:00 ET | Quantum Genomics
Quantum Genomics will receive up to $11 M in payments and 25% minimum up to 30% royalties on future salesTeva will receive an exclusive license to bring firibastat to its home market, Israel PARIS,...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics and its Partners Reach a New Stage of Development in Asia
October 07, 2021 12:00 ET | Quantum Genomics
The phase III REFRESH study has been approved by the regulatory authorities and ethics committees in South Korea and Taiwan.Pre-marketing activities have been intensified with OEP and DongWha. PARIS,...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting
August 27, 2021 04:45 ET | Quantum Genomics
Firibastat is as efficient as the current standard of care (ramipril) in preventing the degradation of the left ventricular ejection fraction (primary endpoint) after myocardial infarction in full...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Enrolls First Patient in Its Pivotal Phase III REFRESH Trial of Firibastat in Difficult-to-Treat and Resistant Hypertension with Once-a-Day Formulation of Firibastat
July 08, 2021 02:00 ET | Quantum Genomics
PARIS, July 08, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the...
Logo_Quantum_Genomics-iloveimg-resized.png
Presentation of the Effects of QGC606 in an Experimental Model of Heart Failure at the Annual Congress of the European Society of Cardiology
July 05, 2021 02:00 ET | Quantum Genomics
PARIS, July 05, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), biopharmaceutical company specializing in the development of a new class of drugs acting directly...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Announces the Publication of New Scientific Article in Biomedicine & Pharmacotherapy Which Further Strengthens its Phase III Development Plan in Difficult to Treat and Resistant Hypertension
May 19, 2021 12:40 ET | Quantum Genomics
PARIS, May 19, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Secures €3 Million Non-dilutive Financing
April 28, 2021 12:04 ET | Quantum Genomics
€1.5 million guaranteed by the French government (PGE) and granted by BNP bank €1.5 million innovation and R&D loan granted by Bpifrance Funding will allow for acceleration of R&D programs ...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Will Present Top-line Results From its QUORUM Study of Firibastat in Heart Failure Post Myocardial Infarction at the European Society of Cardiology (ESC) Meeting
April 21, 2021 02:00 ET | Quantum Genomics
PARIS, April 21, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Announces the End of its Collaboration with Qilu for the Development and Commercialization of Firibastat in China
April 20, 2021 02:00 ET | Quantum Genomics
PARIS and NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Reports Full Year 2020 Operating and Financial Results
March 25, 2021 13:00 ET | Quantum Genomics
Recruitment of first subjects for Phase III trial in difficult-to-treat and resistant arterial hypertension patients Finalization of recruitment for Phase IIb trial in heart failure with upcoming...